Company news
Corcept Therapeutics Incorporated news in 2021
Corcept Therapeutics Incorporated's news releases, calls and decks from 2021, newest first.
Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer
December 19, 2021
Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer
December 15, 2021
Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares
December 14, 2021
Corcept Therapeutics Announces Extension of Previously Announced Tender Offer
December 7, 2021
Corcept Therapeutics to Present at Upcoming Investor Conferences
November 9, 2021
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock
November 7, 2021
Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update
November 2, 2021
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer
September 16, 2021
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021
September 8, 2021
William Guyer to join Corcept as Chief Development Officer
August 11, 2021
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 28, 2021
Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 21, 2021
Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer
July 11, 2021
Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
June 21, 2021
Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
June 14, 2021
Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors
June 9, 2021
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
May 5, 2021
Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)
May 5, 2021
Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer
May 5, 2021
Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess
March 14, 2021
Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
February 28, 2021
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
February 22, 2021
Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update
February 7, 2021
Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call
January 31, 2021
Calls in 2021
- Corcept Therapeutics (NASDAQ:CORT) Q3 2021 Earnings Call
Nov 3, 2021
Transcript - Corcept Therapeutics (NASDAQ:CORT) Q2 2021 Earnings Call
Jul 29, 2021
Transcript - Corcept Therapeutics (NASDAQ:CORT) Q1 2021 Earnings Call
May 6, 2021
Transcript - Corcept Therapeutics (NASDAQ:CORT) Q4 2020 Earnings Call
Feb 8, 2021
Transcript
Decks in 2021
- ESMO 2021
Conference · 17 slides · September 2021